Literature DB >> 24842338

Toward a personalized medicine approach to the management of inflammatory bowel disease.

Mahmoud H Mosli1, William J Sandborn2, Richard B Kim3, Reena Khanna4, Bandar Al-Judaibi5, Brian G Feagan4.   

Abstract

The medical management of inflammatory bowel disease (IBD) is evolving toward a personalized medicine-based model. Modern therapeutic algorithms that feature use of tumor necrosis factor (TNF) antagonists in combination with immunosuppressive are highly effective when initiated in high-risk patients early in the course of disease. Defined targets that guide intensification of therapy are critical interventions. In this model, therapy is optimized through appropriate pretreatment testing, therapeutic drug monitoring, and patient-based monitoring strategies. This review discusses the current application of personalized medicine to the management of IBD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24842338     DOI: 10.1038/ajg.2014.110

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

1.  "Are you a gastroenterologist or a philosopher?".

Authors:  Vincent Baty
Journal:  Am J Gastroenterol       Date:  2015-01       Impact factor: 10.864

Review 2.  Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.

Authors:  Mathurin Flamant; Josselin Rigaill; Stephane Paul; Xavier Roblin
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

Review 3.  Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.

Authors:  Ersilia M DeFilippis; Randy Longman; Michael Harbus; Kyle Dannenberg; Ellen J Scherl
Journal:  Curr Gastroenterol Rep       Date:  2016-03

4.  Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study.

Authors:  Cindy C Y Law; Saranya Sasidharan; Rodrigo Rodrigues; Deanna D Nguyen; Jenny Sauk; John Garber; Cosmas Giallourakis; Ramnik Xavier; Hamed Khalili; Vijay Yajnik; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

Review 5.  Clinical phenotype network: the underlying mechanism for personalized diagnosis and treatment of traditional Chinese medicine.

Authors:  Xuezhong Zhou; Yubing Li; Yonghong Peng; Jingqing Hu; Runshun Zhang; Liyun He; Yinghui Wang; Lijie Jiang; Shiyan Yan; Peng Li; Qi Xie; Baoyan Liu
Journal:  Front Med       Date:  2014-08-12       Impact factor: 4.592

6.  Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.

Authors:  Rikke B Holmstrøm; Ditte V Mogensen; Jørn Brynskov; Mark A Ainsworth; Jacob Nersting; Kjeld Schmiegelow; Casper Steenholdt
Journal:  Dig Dis Sci       Date:  2018-03-21       Impact factor: 3.199

7.  Endoscopy and cross-sectional imaging for assessing Crohn׳s disease activity.

Authors:  Ryan W Stidham; Raymond K Cross
Journal:  Tech Gastrointest Endosc       Date:  2016-07

8.  A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease.

Authors:  Mahmoud H Mosli; Othman Al-Harbi; Brian G Feagan; Majid A Almadi
Journal:  Saudi J Gastroenterol       Date:  2015 Jul-Aug       Impact factor: 2.485

Review 9.  Biomarkers in Search of Precision Medicine in IBD.

Authors:  Ray K Boyapati; Rahul Kalla; Jack Satsangi; Gwo-Tzer Ho
Journal:  Am J Gastroenterol       Date:  2016-09-27       Impact factor: 10.864

Review 10.  Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.

Authors:  Mehmet Coskun; Casper Steenholdt; Nanne K de Boer; Ole Haagen Nielsen
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.